Afya (NASDAQ:AFYA – Get Free Report) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.
Several other equities research analysts have also issued reports on the company. UBS Group dropped their price target on Afya from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of Afya in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $22.00 price target (down from $24.50) on shares of Afya in a research report on Wednesday, January 7th. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.88.
Check Out Our Latest Report on Afya
Afya Stock Performance
Institutional Trading of Afya
Institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP purchased a new position in shares of Afya in the third quarter worth $419,000. Qube Research & Technologies Ltd bought a new stake in Afya in the 3rd quarter worth $610,000. Doma Perpetual Capital Management LLC increased its position in shares of Afya by 50.6% in the third quarter. Doma Perpetual Capital Management LLC now owns 891,639 shares of the company’s stock valued at $13,910,000 after acquiring an additional 299,419 shares during the period. Lazard Asset Management LLC increased its position in shares of Afya by 167.6% in the third quarter. Lazard Asset Management LLC now owns 49,399 shares of the company’s stock valued at $771,000 after acquiring an additional 30,936 shares during the period. Finally, Squarepoint Ops LLC bought a new position in shares of Afya during the third quarter valued at about $191,000. Hedge funds and other institutional investors own 88.02% of the company’s stock.
About Afya
Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.
At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.
Further Reading
- Five stocks we like better than Afya
- Huge robotics rollout underway
- Do not delete, read immediately
- Free: The Crypto Summit That Could Change Your Life
- New gold price target
- But this $2 Gold Stock Before May 20, 2026
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
